Kiadis Pharma N.V. announced that Arthur Lahr will join Kiadis Pharma on January 1, 2017 as Chief Operating Officer and Chief Executive Officer designate. Following five years as CEO, and as the company is advancing into a late stage clinical/pre-commercialization phase, Dr. Rüdiger will hand over his responsibilities as CEO on April 1, 2017 as part of a planned and thoroughly executed succession plan. Arthur Lahr joins Kiadis Pharma with significant experience from within the healthcare sector. Most notably, Mr. Lahr was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson for USD 2.4 billion in 2011.